Information regarding the generic release date for Nurtec ODT is not publicly available at this time. The patent landscape for Nurtec ODT, including its exclusivity periods, is subject to ongoing developments.
When might generic Nurtec ODT become available?
The availability of generic versions of prescription drugs is typically tied to the expiration of patents and other market exclusivities held by the original manufacturer. For Nurtec ODT, the specific patent expiration dates and any potential for early challenges or settlements would determine when generic versions could be legally manufactured and sold. Detailed information on patent status and potential generic entry dates can often be found through specialized patent tracking services.
What is Nurtec ODT used for?
Nurtec ODT (rimegepant) is a prescription oral dissolving tablet approved for the acute treatment of migraine with or without aura in adults [1]. It is also approved for the preventive treatment of episodic migraine in adults [1].
How does Nurtec ODT work?
Nurtec ODT contains the active ingredient rimegepant, which is a calcitonin gene-related peptide (CGRP) receptor antagonist [1]. CGRP is a molecule that plays a role in migraine attacks. By blocking the CGRP receptor, rimegepant is believed to help reduce migraine pain and other symptoms [1].
Are there other treatments for migraine?
Yes, there are various treatment options for migraine, including other CGRP antagonists, triptans, and preventive medications like beta-blockers and anticonvulsants [2]. The choice of treatment depends on individual patient needs, symptom frequency, and severity.
What are the potential side effects of Nurtec ODT?
Common side effects reported for Nurtec ODT include nausea and indigestion [1].
Who manufactures Nurtec ODT?
Nurtec ODT is manufactured by Biohaven Pharmaceuticals, which is now part of Pfizer [3].
*
**Sources
1. https://www.nurtec.com/
2. https://www.mayoclinic.org/diseases-conditions/migraine-headache/diagnosis-treatment/drc-20360202
3. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-biohaven-pharmaceuticals-holding